Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Investor Presentation (December 2022)
38 slides from Alzecure Pharma Ab's investor presentation, Dec 6, 2022
Slide 1: Rights issue presentation: Developing therapies for Alzheimer's & Pain
Rights issue presentation December 2022 Developing therapies for Alzheimer’s & Pain Martin Jönsson, CEO
Slide 2: Disclaimer
Disclaimer The information in this presentation does not contain nor constitute an offer to acquire, subscribe for or in any other way trade with shares, warrants or other securities in AlzeCure Pharma AB (“AlzeCure”). No measures have been taken and no measures will be taken in order to allow for a
Slide 3: Agenda
Agenda • Who we are • Focus areas • Pipeline & the science • Progress & goals, incl. Rights Issue
Slide 4: AlzeCure Pharma – in brief
AlzeCure Pharma – in brief Ø Working in Alzheimer’s Disease (AD) and Pain – Hugh unmet medical need & multi-billion sales potential Ø Founded in 2016, out of a research founda1on sponsored by Alzheimerfonden Ø Spin-out from AstraZeneca – as a result of them ending their CNS projects 2012 Ø Experienc
Slide 5: Our Business Model
Our Business Model • We are a Research & Development company • Research & develop through early clinical phase and then to out-license or partner on our projects • Gain incomes through: − Upfront payments − Milestone payments − Royalties on sold products 5
Slide 6: Small molecule drugs – AlzeCure's approach for increased success
Small molecule drugs – AlzeCure’s approach for increased success DIFFERENCES BETWEEN SMALL MOLECULES & BIOLOGICS* SMALL MOLECULE LARGE BIOLOGIC DRUG AlzeCure focus Monoclonal antibody Small molecule drug c. 25,000 atoms Smaller molecules can have increased likelihood of penetrating the Blood Brain B
Slide 7: A pipeline of small-molecule programs
A pipeline of small-molecule programs – Multiple candidates increase chance of success Platform Candidate Indication Research phase Preclinical phase Phase I Phase II Phase III NeuroRestore® Alzheimer’s Disease, Sleep disorders, Positive read-out Phase I trial ACD856 Traumatic brain injuries Parkins
Slide 8: Close cooperation with leading experts & institutions
Close cooperation with leading experts & institutions Professor Bengt Winblad Professor Maria Eriksdotter Professor Henrik Zetterberg Karolinska Institute Karolinska Institute Sahlgrenska and UCL
Slide 9: Alzheimer's Disease – our primary focus area
Our primary Focus area Alzheimer’s Disease • Costs the society more than oncology and cardiovascular diseases TOGETHER • The patient population and costs are expected to TRIPLE in the next 30 years 9
Slide 10: Tripling patient population – due to the aging population
Tripling patient population – due to the aging population 150m 75m 50m 2020 2030 2050 • 50 million people worldwide live with dementia … • … and doubling every 20 years • Alzheimer’s accounts for 60 - 80% of all dementia cases 10
Slide 11: Alzheimer's Disease – Progressive & lethal disorder with lack of therapies
Alzheimer’s Disease – Progressive & lethal disorder with lack of therapies Pre-symptomatic Alzheimer’s 10 - 20 years prior to symptoms § In Pre-symptomatic Alzheimer’s, Aβ amyloid Symptomatic Alzheimer’s 7 - 10 years life expectancy § The stage includes dying neurons in the brain † pathology & plack
Slide 12: Therapy Definitions – Symptomatic, Disease modifying & Prevention therapies
Therapy Definitions - Symptomatic, Disease modifying & Prevention therapies Alzheimer disease progression Start of treatment Prevention therapy Cognitive Performance Symptomatic therapy Disease modifying therapy Age/Time 12 Confidential, Copy right
Slide 13: Two Alzheimer's platforms – 1st-in-class properties & potential game-changers
Two Alzheimer’s platforms - 1st-in-class properties & potential game-changers TARGET TWO KEY AREAS WITH A HIGH UNMET MEDICAL NEED Preventive & Symptomatic & pot. Disease-modifying therapy Disease-modifying therapy AlzstaCn® NeuroRestore® Targe;ng Amyloid Produc;on Improving Neuronal Function - Novel
Slide 14: Alzstatin – Preventive & Disease Modifying against Alzheimer's
Alzstatin® - Preventive & Disease Modifying against Alzheimer’s
Slide 15: The Alzheimer's brain and its destruction
Alzstatin® The Alzheimer’s brain and its destruction Toxic protein formations – Aβ-42 amyloid pathology & plaque – are harming and destroying the brain. The formation process is called the Amyloid Cascade Toxic protein formations, built up of Aβ-42, are harming and destroying the brain structures.
Slide 16: The Amyloid Cascade
Alzstatin® The Amyloid Cascade - Generates toxic & damaging fragments, including plaques, destroying neurons & brain structures AlzeCure’s GSM* Alzstatin® reduces Aβ -42 to diminish the build-up of toxic fragments & plaque 16 *) GSM = Gamma Secretes Modulator
Slide 17: 2AlzeCure
2AlzeCure
Slide 18: Alzheimer's Disease Modifier – Preventing or delaying Disease Progression
Alzstatin® Alzheimer’s Disease Modifier – Preventing or delaying Disease Progression ALZHEIMER'S DISEASE PROGRESSION Aβ-42 - main culprit in Alzheimer progression Pre-symptomatic Alzheimer Symptoma4c Alzheimer 10-20 years 7-10 years Aggregation effect Amyloid plaques Clustering effect Abnormal Area w
Slide 19: Target patient population – Alzstatin vs Antibodies
Alzstatin® Brain status at intended treatment initiation Target patient population - Alzstatin ® vs Antibodies Alzstatin® Antibodies Healthy brain at risk Mild Alzheimer’s of Alzheimer’s • The antibody Aduhelm has the indication, “Mild Alzheimer’s disease”*, where the brain is already heavily damage
Slide 20: How Alzstatin is expected to differ from the Antibodies
Alzstatin® How Alzstatin is expected to differ from the Antibodies* - Key advantages • Small molecule therapy − Small molecules generally pass much more readily across the BBB to its target site - the brain − Provides a more cost-effective treatment for chronic use than biologics • Oral formulation =
Slide 21: NeuroRestore – A cognitive enhancer with neuroprotective potential
NeuroRestore® - A cognitive enhancer with neuroprotective potential and multiple possible indications
Slide 22: The NeuroRestore platform
The NeuroRestore platform – Novel symptomatic treatments, enhancing neurotrophic signalling and synaptic plasticity • Platform NeuroRestore – Novel Symptomatic Treatments
Slide 23: The biological pathway explored in NeuroRestore
The biological pathway explored in NeuroRestore® NeuroRestore® enhances neuronal function & cognitive capabilities + The compounds, e.g. ACD856, • AlzeCure’s compounds act as BDNF/ acts as enhancers of enhancers of neurotrophin, e.g. NGF neurotrophin, e.g. BDNF/NGF signalling, and the BDNF and NGF s
Slide 24: NeuroRestore – Cognitive Enhancer Improving Learning and Memory Ability
NeuroRestore - Cognitive Enhancer Improving Learning and Memory Ability Stages of memory formation LEARN STORE REMEMBER Transforming Maintaining the Re-accessing the information into a form encoded information from that can be stored in information in the past which has memory memory been encoded an
Slide 25: Positive results in our phase 1 with NeuroRestore ACD856
Press release Positive results in our phase 1 with NeuroRestore ACD856 https://www.alzecurepharma.se/en/alzecures-alzheimers-project-neurorestore-acd856-shows-positive-effect-on-brain-activity-in-clinical-trial/
Slide 26: NeuroRestore – Potential Disease Modifying effect
Press release NeuroRestore - Potential Disease Modifying effect https://www.alzecurepharma.se/en/alzecure-gets-abstract-accepted-on-potential-neuroprotective-effects-of-neurorestore-acd856/
Slide 27: NeuroRestore ACD856 – Candidate in clinical trials
Press release NeuroRestore ACD856 – Candidate in clinical trials - Patent in the US to 2039 https://www.alzecurepharma.se/en/alzecure-receives-us-patent-for-neurorestore-acd856/
Slide 28: Chronic Pain – our second focus area
Our second Focus area Chronic Pain • Suicide due to chronic pain is as common as due to depression • Most common cause for sick leaves, creating misery & high societal costs • Opioid crisis in the US - is huge & reversing the mean average lifespan of Americans Huge need for more efficacious and safer
Slide 29: Our platform PAINLESS – Targeting unmet medical needs within pain
Our platform PAINLESS – Targeting unmet medical needs within pain Osteoarthritis & severe Neuropathic pain* pain conditions > 300 million patients 600 million paHents Project: TrkA-NAM Project: ACD440 29 *) Neuropathic pain = Pain initiated or caused by a primary lesion or dysfunction in the somatos
Slide 30: Professor David Julius, Nobel prize medicine laureate 2021
Professor David Julius Nobel prize medicine laureate 2021 University of California, San Francisco, USA Prize motivation: … for the discoveries of receptor (TRPV1) for temperature and touch. The identification of and knowledge about the TRPV1* receptor is central for the mediation of neuropathic pain
Slide 31: ACD440 – Novel TRPV1 antagonist in clinical phase for neuropathic pain
Painless ACD440 – Novel TRPV1 antagonist in clinical phase for neuropathic pain PROJECT OVERVIEW › Approximately SEK 200m already invested on project development Emanates from › Mode of acSon confirmed in several Phase 1 clinical trials Big Pharma › Synthesized compound and formulaHon developed › The
Slide 32: Neuropathic pain – Fast growing market
Neuropathic pain - Fast growing market • The most valuable segment within the pain indications • Poorly served patients • Huge demand for better drugs 2020 CAGR to 2027 $11 billions 12.9% => $25 billions The Neuropathic Pain market was valued at $10,8 billion in 2020 globally and is forecast to reac
Slide 33: TrkA-NAM – Non-Opioid treatment of severe pain conditions
Painless TrkA-NAM – Non-Opioid treatment of severe pain conditions Attractive E.g. osteoarthritis in patients who have experienced insufficient pain Target population relief from 1st line standard of care or unacceptable side effects Clinical Mechanism with strong validation – step-changing clinical
Slide 34: Successful 2022 … now getting ready for 2023
Successful 2022 … now getting ready for 2023
Slide 35: Key milestones & activities in 2023
Key milestones & activities in 2023 m Out-license or partner on one of AlzeCure´s projects in the Alzheimer’s or Pain area Pre-IND mee#ng on NeuroRestore® ACD856 with FDA to prepare next clinical study Progress Alzstatin® ACD680 into the next phase, pre-clinical development Advance Painless TrkA-NAM
Slide 36: Rights Issue – SEK 31.7 million, >80% guaranteed
Right Issue – subscription period: December 6 – 20 2022 Amount SEK 31.7 million – >80% guaranteed Over-allotment option: up to SEK 15.0 million Visit our home page to learn more. www.alzecurepharma.com
Slide 37: Key investment highlights in AlzeCure
Key investment highlights in AlzeCure Targeting areas of huge unmet medical needs m Strong team with extensive experience and track record Platforms with first-in-class properties and potential game-changers Parallel investments in several candidates and potent follow-up programs Multi-billion dolla
Slide 38: Karolinska Institutet Novum Science Park, Stockholm
Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN www.alzecurepharma.com
AlzeCure Pharma — Investor Presentation (December 2022) on 6ix